Results 71 to 80 of about 1,483,959 (183)
JAK2V617F is a gain of function point mutation that occurs in Myeloproliferative Neoplasm (MPN) patients and deranges their hemopoiesis at cellular level. We speculate that hyperfunctioning JAK2 can modify osteoclast (OCL) homeostasis in MPN patients. We
Emmanouil Spanoudakis +7 more
doaj +1 more source
ABSTRACT Introduction Erythromelalgia is a rare disorder characterised by burning pain, erythema and increased skin temperature in the extremities. Its pathophysiological heterogeneity, together with variable treatment responses, complicates management in the absence of evidence‐based guidelines.
Camille Racca +8 more
wiley +1 more source
Introduction Janus kinase2 (JAK2) V617F mutation in myeloid cells has been reported from the majority of patients with Polycythemia vera (PV). Materials & Methods A cross sectional study was conducted to review clinical records of 93 cases of ...
Deepti Mutreja +6 more
doaj
Background The JAK2-STAT signaling pathway plays a critical role in myeloproliferative neoplasms (MPN). An activating mutation in JAK2 (V617F) is present in ~ 95% of polycythemia vera, essential thrombocythemia, and primary myelofibrosis cases.
Min Hu +9 more
doaj +1 more source
To examine the clinical characteristics and prognosis of cerebral venous sinus thrombosis (CVST) that presented as pseudotumor cerebri (PTC) patients with JAK2V617F mutation.
O. Zloto +5 more
semanticscholar +1 more source
ABSTRACT Philadelphia‐negative myeloproliferative neoplasms (MPN), a spectrum of blood malignancies characterized by uncontrolled myeloid proliferation, persist as a key challenge in onco‐hematology due to their intricate molecular background, heterogeneous clinical phenotypes, and variable prognoses.
Mariagiovanna Ballato +8 more
wiley +1 more source
Incidence of the JAK2V617F Mutation in Chronic Myeloproliferative Disorders
Amaç: Orta Karadeniz Bölgesi’nde BCR/ABL negatif kronik miyeloproliferatif hastalık (KMH) tanısıyla takip edilen olguların JAK2V617F mutasyon sıklığı ve bu mutasyonun hastalığın klinik özelliklerine etkisi açısından incelenmesi amaçlanmıştır.
DEMİR, Ayşe Kevser +5 more
openaire +2 more sources
To date, a plenty of techniques for the detection of JAK2V617F is used over different laboratories, with substantial differences in specificity and sensitivity.
M. Perricone +44 more
semanticscholar +1 more source
ABSTRACT The SH2B3 gene, also known as LNK, encodes an adaptor protein that negatively regulates key hematopoietic signaling pathways, including JAK–STAT, MAPK, and PI3K/AKT, thereby maintaining hematopoietic homeostasis. SH2B3 interacts with major signaling regulators such as JAK2, MPL, FLT3, and KIT. Loss‐of‐function alterations have been reported in
Marta Rachele Stefanucci +9 more
wiley +1 more source
Most patients with polycythemia vera (PV) and half of essential thrombocythemia (ET) possess an activating JAK2V617F mutation. The objective of this study was to better define the effect of JAK2V617F mutant allele burden on clinical phenotypes in Chinese
Shixiang Zhao +7 more
semanticscholar +1 more source

